↓ Skip to main content

Dove Medical Press

Article Metrics

Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration

Overview of attention for article published in Drug Design, Development and Therapy, June 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
46 Dimensions

Readers on

mendeley
56 Mendeley
Title
Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
Published in
Drug Design, Development and Therapy, June 2013
DOI 10.2147/dddt.s43470
Pubmed ID
Authors

Ilias Georgalas, Perganta, Vakalis, Vachtsevanos, Tranos, Solon Asteriades, Koukoula

Abstract

Age-related macular degeneration (AMD) is the main cause of visual impairment and blindness in people aged over 65 years in developed countries. Vascular endothelial growth factor (VEGF) is a positive regulator of angiogenesis and its proven role in the pathological neovascularization in wet AMD has provided evidence for the use of anti-VEGF agents as potential therapies. In this study, we review the literature for the possible causes of failure after treatment with anti-VEGF agents and attempt to propose an algorithm of suggestive actions to increase the chances of successful management of such difficult cases.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
France 1 2%
Switzerland 1 2%
Unknown 54 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 10 18%
Student > Master 10 18%
Researcher 9 16%
Professor 5 9%
Student > Bachelor 5 9%
Other 9 16%
Unknown 8 14%
Readers by discipline Count As %
Medicine and Dentistry 20 36%
Agricultural and Biological Sciences 11 20%
Biochemistry, Genetics and Molecular Biology 4 7%
Pharmacology, Toxicology and Pharmaceutical Science 4 7%
Economics, Econometrics and Finance 2 4%
Other 5 9%
Unknown 10 18%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 July 2013.
All research outputs
#9,607,941
of 12,510,237 outputs
Outputs from Drug Design, Development and Therapy
#675
of 1,315 outputs
Outputs of similar age
#96,182
of 149,588 outputs
Outputs of similar age from Drug Design, Development and Therapy
#18
of 36 outputs
Altmetric has tracked 12,510,237 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,315 research outputs from this source. They receive a mean Attention Score of 4.5. This one is in the 42nd percentile – i.e., 42% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 149,588 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.